The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.
 
Yelena Yuriy Janjigian
Consulting or Advisory Role - Lilly; Pfizer
Research Funding - Amgen; Bayer; Boehringer Ingelheim; Genentech; Lilly; Roche
 
Patrick Alexander Ott
Consulting or Advisory Role - Alexion Pharmaceuticals; Amgen; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Genentech; Neon Therapeutics
Research Funding - ARMO BioSciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Merck (Inst)
 
Emiliano Calvo
Consulting or Advisory Role - Astellas Pharma; GlaxoSmithKline; Lilly/ImClone; Nanobiotix; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Novartis
Research Funding - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Janssen Oncology; Lilly; Merck; Millennium; Nektar; Novartis; OncoMed; Pfizer; PharmaMar; PsiOxus Therapeutics; Puma Biotechnology; Roche/Genentech; Sanofi; Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - Lilly; Novartis; PsiOxus Therapeutics
Other Relationship - Pierre Fabre
 
Joseph W. Kim
Consulting or Advisory Role - Dendreon; TRM Oncology; Voluntis
Research Funding - Immune Design
 
Paolo Antonio Ascierto
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
Padmanee Sharma
Stock and Other Ownership Interests - Evelo Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company; Kite, a Gilead company (I); Neon Therapeutics; Neon Therapeutics (I)
Consulting or Advisory Role - Amgen; Amgen (I); AstraZeneca; AstraZeneca (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); Constellation Pharmaceuticals; Constellation Pharmaceuticals (I); EMD Serono; EMD Serono (I); Evelo Therapeutics; Evelo Therapeutics (I); GlaxoSmithKline; GlaxoSmithKline (I); Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company (I); Neon Therapeutics; Neon Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Katriina Johanna Peltola
Employment - Orion
Stock and Other Ownership Interests - Faron Pharmaceuticals
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Orion; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Dirk Jaeger
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Roche
 
T.R. Jeffry Evans
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Baxter (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Eisai (Inst); Karus Therapeutics (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Celgene
Research Funding - AstraZeneca (Inst); Basilea (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunicon (Inst); Lilly (Inst); Merck (Inst); Verastem (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Filippo G. De Braud
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD; Novartis; SERVIER; Tiziana Life Sciences
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Fond; Lilly; Menarini; Roche
 
Ian Chau
Honoraria - Amgen; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; MSD Oncology; Roche/Genentech; Sanofi
Research Funding - Janssen-Cilag (Inst); Merck Serono (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Lilly; Merck Serono; MSD; Sanofi
 
Marina Tschaika
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Christopher T. Harbison
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Weiguo Cai
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Dung T. Le
Honoraria - Merck
Consulting or Advisory Role - Merck
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Merck